newsfilter
← Earnings
Earnings Releases·

Rhythm Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Net product revenue from IMCIVREE reached $92.1 million in Q3 2026, a 79% year-over-year increase and 29% sequential rise, driven by U.S. demand for acquired HO and BBS; net loss narrowed to $(42.4) million compared to $(54.3) million in the prior year quarter.
  • Full-year 2026 guidance sets Non-GAAP operating expenses between $360 million and $380 million, with GAAP R&D and SG&A projected at $165–175 million and $195–205 million respectively, supported by a cash position sufficient for at least 24 months of operations.
  • Strategic capital management includes a $750 million term loan facility and an amended LG Chem agreement reducing royalties to 1% in exchange for $350 million in fixed payments over four years.
  • Commercial expansion continues with IMCIVREE launches in Japan and Europe, while pipeline milestones include initiating a pivotal Phase 3 trial for bivamelagon in acquired HO by year-end 2026 and completing RM-718 enrollment in the second half of 2026.
Company
RHYTHM PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology